Skip to content
  • Tuesday, 27 October 2026
  • 5:11 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases
Pharmaceutical R&D

Terremoto Biosciences Secures $108 Million Series C to Advance Next-Generation AKT1 Inhibitors for Oncology and Rare Diseases

Teuku Ryan Apr 16, 2026 0

Terremoto Biosciences, a pioneering biotechnology company at the forefront of developing novel therapeutics targeting the PI3K/AKT pathway, announced today the…

Read More
New Year, New Goggles: Resetting Your Lab Safety GameControlling diabetes without insulin injections thanks to new implantNovo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatideAI-powered whale-spotting tech may help save San Francisco Bay’s gray whales
The Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals PlummetJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactEliquis Loss of Exclusivity: A Pharmaceutical Patent Cliff of Historic ProportionsMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric Growth
Merck and Moderna’s cancer vaccine is customized for each patient’s tumorAn Unbiased Look at Google Gemini Omni: Features, Costs, and Market ComparisonESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial CancerLight-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Merck and Moderna’s cancer vaccine is customized for each patient’s tumor
Lana Keisha Oct 27, 2026
Data Science & Bioinformatics
An Unbiased Look at Google Gemini Omni: Features, Costs, and Market Comparison
Evan Lee Salim Oct 27, 2026
Pharmaceutical R&D
ESMO 2026: Sacituzumab Tirumotecan Sets New Survival Benchmark in Recurrent Endometrial Cancer
Teuku Ryan Oct 27, 2026
Advanced Materials Science
Light-Driven Magnetism Breakthrough Promises Ultrafast, High-Density Digital Data Storage
Nila Kartika Wati Oct 27, 2026

Copyright © 2026 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ